These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31442331)

  • 1. Neurokinin 1 receptor antagonists exhibit peripheral effects in prurigo nodularis including reduced ERK1/2 activation.
    Agelopoulos K; Rülander F; Dangelmaier J; Lotts T; Osada N; Metze D; Luger TA; Loser K; Ständer S
    J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):2371-2379. PubMed ID: 31442331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substance P Receptor Antagonist Suppresses Inflammatory Cytokine Expression in Human Disc Cells.
    Kepler CK; Markova DZ; Koerner JD; Mendelis J; Chen CM; Vaccaro AR; Risbud MV; Albert TJ; Anderson DG
    Spine (Phila Pa 1976); 2015 Aug; 40(16):1261-9. PubMed ID: 25929203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant.
    Ohanyan T; Schoepke N; Eirefelt S; Hoey G; Koopmann W; Hawro T; Maurer M; Metz M
    Acta Derm Venereol; 2018 Jan; 98(1):26-31. PubMed ID: 28853492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomic and Phosphoproteomic Analysis Reveals that Neurokinin-1 Receptor (NK1R) Blockade with Aprepitant in Human Keratinocytes Activates a Distinct Subdomain of EGFR Signaling: Implications for the Anti-Pruritic Activity of NK1R Antagonists.
    Kwatra SG; Boozalis E; Huang AH; Nanni C; Khanna R; Williams KA; Semenov YR; Roberts CM; Burns RF; Krischak M; Kwatra MM
    Medicines (Basel); 2019 Dec; 6(4):. PubMed ID: 31835310
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurokinin Receptor 1 (NK1R) Antagonist Aprepitant Enhances Hematoma Clearance by Regulating Microglial Polarization via PKC/p38MAPK/NFκB Pathway After Experimental Intracerebral Hemorrhage in Mice.
    Jin P; Deng S; Sherchan P; Cui Y; Huang L; Li G; Lian L; Xie S; Lenahan C; Travis ZD; Zhang JH; Gong Y; Tang J
    Neurotherapeutics; 2021 Jul; 18(3):1922-1938. PubMed ID: 34244927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
    Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
    J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU).
    Tsianakas A; Zeidler C; Riepe C; Borowski M; Forner C; Gerss J; Metz M; Staubach P; Raap U; Kaatz M; Urban M; Luger TA; Ständer S
    Acta Derm Venereol; 2019 Apr; 99(4):379-385. PubMed ID: 30653242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of aprepitant, a clinically used neurokinin-1 receptor antagonist on the expression of conditioned psychostimulant versus opioid reward.
    Mannangatti P; Sundaramurthy S; Ramamoorthy S; Jayanthi LD
    Psychopharmacology (Berl); 2017 Feb; 234(4):695-705. PubMed ID: 28013351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV.
    Barrett JS; Spitsin S; Moorthy G; Barrett K; Baker K; Lackner A; Tulic F; Winters A; Evans DL; Douglas SD
    J Transl Med; 2016 May; 14(1):148. PubMed ID: 27230663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial.
    Ständer S; Kwon P; Hirman J; Perlman AJ; Weisshaar E; Metz M; Luger TA;
    J Am Acad Dermatol; 2019 May; 80(5):1395-1402. PubMed ID: 30894279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of SP/NK1R on expression and activity of glutaredoxin and thioredoxin proteins in prostate cancer cells.
    Zarei Shandiz S; Assaran Darban R; Javid H; Ghahremanloo A; Hashemy SI
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Aug; 397(8):5875-5882. PubMed ID: 38334824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effects of Neurokinin-1 Receptor Antagonist in an Experimental Autoimmune Cystitis Model Resembling Bladder Pain Syndrome/Interstitial Cystitis.
    Liu BK; Jin XW; Lu HZ; Zhang X; Zhao ZH; Shao Y
    Inflammation; 2019 Feb; 42(1):246-254. PubMed ID: 30196377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurokinin 1 Receptor Antagonists for Pruritus.
    Alam M; Buddenkotte J; Ahmad F; Steinhoff M
    Drugs; 2021 Apr; 81(6):621-634. PubMed ID: 33675531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.
    Manak MM; Moshkoff DA; Nguyen LT; Meshki J; Tebas P; Tuluc F; Douglas SD
    AIDS; 2010 Nov; 24(18):2789-96. PubMed ID: 20975512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
    Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
    Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TGFβ regulates NK1R-Tr to affect the proliferation and apoptosis of breast cancer cells.
    Wang L; Wang N; Zhang R; Dong D; Liu R; Zhang L; Ji W; Yu M; Zhang F; Niu R; Zhou Y
    Life Sci; 2020 Sep; 256():117674. PubMed ID: 32380077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential therapeutic effect of NK1R antagonist in diabetic non-healing wound and depression.
    Li M; Ma H; Zhang S; Peng Y; Ding L; Zhang Y; Min P
    Front Endocrinol (Lausanne); 2022; 13():1077514. PubMed ID: 36686487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to Aprepitant.
    Bashash D; Safaroghli-Azar A; Bayati S; Razani E; Pourbagheri-Sigaroodi A; Gharehbaghian A; Momeny M; Sanjadi M; Rezaie-Tavirani M; Ghaffari SH
    Int J Biochem Cell Biol; 2018 Oct; 103():105-114. PubMed ID: 30145367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells.
    Garnier A; Vykoukal J; Hubertus J; Alt E; von Schweinitz D; Kappler R; Berger M; Ilmer M
    Int J Oncol; 2015 Jul; 47(1):151-60. PubMed ID: 25998227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular and behavioral effects of lipopolysaccharide treatment are dependent upon neurokinin-1 receptor activation.
    Fulenwider HD; Smith BM; Nichenko AS; Carpenter JM; Nennig SE; Cheng K; Rice KC; Schank JR
    J Neuroinflammation; 2018 Feb; 15(1):60. PubMed ID: 29486768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.